ORAGENICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
ORAGENICS, INC. (OGEN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $819.84 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2026-03-16
- ORAGENICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2025 was $819.84K, a 168.24% increase from fiscal 2024.
- ORAGENICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2024 was $305.63K, a 4.88% increase from fiscal 2023.
- ORAGENICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2023 was $291.40K, a 3001.66% increase from fiscal 2022.
- ORAGENICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2022 was $9.39K, a 99.47% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month as first filed |
|---|---|---|
| 2025-12-31 | $819.84K 10-K · filed 2026-03-16 | |
| 2024-12-31 | $305.63K 10-K · filed 2026-03-16 | |
| 2023-12-31 | $291.40K 10-K · filed 2025-03-14 | |
| 2022-12-31 | $9.39K 10-K · filed 2024-03-29 | |
| 2021-12-31 | $1.78M 10-K · filed 2023-04-17 | |
| 2020-12-31 | $1.21M 10-K/A · filed 2022-07-29 | |
| 2019-12-31 | $522.36K 10-K · filed 2021-03-01 | |
| 2018-12-31 | $1.29M 10-K · filed 2020-03-04 | $652.88K 10-K · filed 2019-03-29 |
| 2017-12-31 | $445.59K 10-K · filed 2019-03-29 | |
| 2016-12-31 | $572.79K 10-K · filed 2018-02-16 | |
| 2015-12-31 | $325.36K 10-K · filed 2017-02-27 | |
| 2014-12-31 | $257.01K 10-K · filed 2016-03-30 | |
| 2013-12-31 | $166.51K 10-K · filed 2015-02-27 | |
| 2012-12-31 | $547.56K 10-K · filed 2014-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |